Daniel De Vos
Innogenetics
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel De Vos.
Journal of Reproductive Immunology | 2009
Hans Verstraelen; Rita Verhelst; Lieve Nuytinck; Kristien Roelens; Els de Meester; Daniel De Vos; Martine van Thielen; Rudi Rossau; Wim Delva; Ellen De Backer; Mario Vaneechoutte; Marleen Temmerman
Host genetic factors have previously been found to act as determinants of differential susceptibility to major infectious diseases. It is less clear whether such polymorphisms may also impose on pathogen recognition in mucosal overgrowth conditions such as bacterial vaginosis, an anaerobic overgrowth condition characterised by the presence of a vaginal biofilm consisting of the Gram-positive anaerobes Gardnerella vaginalis and Atopobium vaginae. We selected 34 single nucleotide polymorphisms pertaining to 9 genes involved with Toll-like receptor-mediated pathogen recognition and/or regulation (LBP, CD14, TLR1, TLR2, TLR4, TLR6, MD2, CARD15 and SIGIRR) and assessed in a nested case-control study their putative association with bacterial vaginosis, as diagnosed by Gram staining, and with the vaginal carriage of A. vaginae and G. vaginalis, as determined by species-specific PCR, among 144 pregnant women. Carriage of G. vaginalis during early pregnancy was associated with the -1155A>G substitution in the promoter region of the MD2 gene (p=0.041). The presence of A. vaginae during the first half of the pregnancy was significantly associated with the CD14 intron 2 1342G>T (p=0.039), the TLR1 exon 4 743A>G (p=0.038), and the CARD15 exon 4 14772A>T (p=0.012) polymorphisms, and marginally significantly associated with the LBP exon13 26842C>T (p=0.056), the CD14 promoter -260C>T (p=0.052), and the TLR1 promoter -7202A>G (p=0.062) polymorphisms. However, no association between gene polymorphisms and bacterial vaginosis as such could be documented. Our data suggest that some degree of genetic susceptibility involving pathogen recognition may occur with the key bacterial vaginosis organism, A. vaginae.
Methods of Molecular Biology | 2006
Geert Jannes; Daniel De Vos
Nucleic acid-based diagnostics gradually are replacing or complementing culture-based, biochemical, and immunological assays in routine microbiology laboratories. Similar to conventional tests, the first-generation deoxyribonucleic acid assays determined only a single analyte. Recent improvements in detection technologies have paved the way for the development of multiparameter assays using macroarrays or micro-arrays, while the introduction of closed-tube real-time polymerase chain reaction systems has resulted in the development of rapid microbial diagnostics with a reduced contamination risk. The use of these new molecular technologies is not restricted to detection and identification of microbial pathogens but also can be used for genotyping, allowing one to determine antibiotic resistance or to perform microbial fingerprinting.
MicrobiologyOpen | 2014
Maarten G. K. Ghequire; Jozef Dingemans; Jean-Paul Pirnay; Daniel De Vos; Pierre Cornelis; Ren e De Mot
Lectin‐like bacteriocins of the LlpA family, originally identified in plant‐associated bacteria, are narrow‐spectrum antibacterial proteins composed of two tandemly organized monocot mannose‐binding lectin (MMBL) domains. The LlpA‐like bacteriocin of Pseudomonas aeruginosa C1433, pyocin L1, lacks any similarity to known P. aeruginosa bacteriocins. The initial interaction of pyocin L1 with target cells is mediated by binding to d‐rhamnose, present in the common polysaccharide antigen of lipopolysaccharides (LPS), but the actual cytotoxic mechanism is unknown. In this study, we characterized the activity range of pyocin L1 and two additional L pyocins revealed by genome mining, representing two highly diverged LlpA groups in P. aeruginosa. The recombinant proteins exhibit species‐specific antagonistic activities down to nanomolar concentrations against clinical and environmental P. aeruginosa strains, including several multidrug‐resistant isolates. The overlap in target strain spectrum between two close homologues of the pyocin L1 group is only minimal, contrasting with the considerable spectral redundancy of LlpA proteins reported for other Pseudomonas species. No correlation was found between L pyocin susceptibility and phylogenetic relatedness of P. aeruginosa isolates. Sensitive strains were retrieved in 13 out of 15 O serotypes tested, excluding the possibility that the highly variable and immunogenic O serotype antigen of the LPS coating would represent a dominant susceptibility‐discriminating factor.
Archive | 2018
Jean-Paul Pirnay; Maia Merabishvili; Hilde Van Raemdonck; Daniel De Vos; Gilbert Verbeken
In this chapter we review bacteriophage production requirements to help institutions, which wish to manufacture bacteriophage products for human use in compliance with the applicable regulatory expectancies, defining production processes and implementing relevant controls ensuring quality, safety, and efficacy of the final products. The information disclosed in this chapter can also serve as a basis for discussions with competent authorities regarding the development of expedited bacteriophage product development and licensing pathways, including relevant and pragmatic requirements, and allowing for the full exploitation of bacteriophages as natural controllers of bacterial populations.
Archive | 2018
Maia Merabishvili; Jean-Paul Pirnay; Daniel De Vos
Correctly designed bacteriophage therapeutics are the cornerstone for a successful outcome of bacteriophage therapy. Here we overview strategies on how to choose bacteriophages and their bacterial hosts at different steps of a bacteriophage cocktail development in order to comply with all quality and safety requirements based on the already existing essentially empirical experience in bacteriophage therapy and current accomplishments in modern biomedical sciences. A modification of the classic Appelmans method (1922) to assess stability of bacteriophage activity in liquid media is presented in order to improve the overall performance of therapeutic bacteriophages individually and collectively in the cocktail.
Environmental Microbiology | 2005
Jean-Paul Pirnay; Sandra Matthijs; Huri Colak; Patrice Chablain; Florence Bilocq; Johan Van Eldere; Daniel De Vos; Martin Zizi; Ludwig Triest; Pierre Cornelis
Critical Care | 2000
Jean-Paul Pirnay; Daniel De Vos; Luc Duinslaeger; Pascal Reper; Christian Vandenvelde; Pierre Cornelis; Alain Vanderkelen
Archive | 2003
Gerd Haberhausen; Thomas Emrich; Rudi Rossasu; Geert Jannes; Daniel De Vos
Archive | 2017
Isa Serrano; Daniel De Vos; José Pedro Santos; Florence Bilocq; Alexandre Leitão; Luís Tavares; Jean-Paul Pirnay; Manuela Oliveira
Archive | 2014
Thomas Rose; Gilbert Verbeken; Daniel De Vos; Maya Merabishvili; Mario Vaneechoutte; Serge Jennes; Martin Zizi; Jean-Paul Pirnay